CKLF like MARVEL transmembrane domain containing 6Genealiases: CKLFSF6 · PRO2219
Q-omics provides the consensus-scored CMTM6 profile across patient tissues and cancer cell-line models. CMTM6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CMTM6 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, CMTM6 RNA expression shows 19,814 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and BLCA as cancer lineages where CMTM6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CMTM6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CMTM6 survival associations across molecular data types. CMTM6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CMTM6 RNA expression–survival associations across cancer types. High CMTM6 expression shows unfavorable associations in ACC, LGG, MESO and KICH, but favorable associations in BRCA and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CMTM6 RNA expression.
This table summarizes CMTM6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CMTM6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CMTM6 shows lower tumor expression in KICH, LUSC and LIHC and higher tumor expression in BLCA, STAD and BRCA. The BLCA box plot shows higher CMTM6 RNA expression in tumor versus normal tissue (log2 FC = +1.572, t-test p < 0.001).
This table shows molecular features associated with CMTM6 in patient tissues and cancer cell lines. In patient samples, CMTM6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CMTM6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
